Novo Nordisk, Inc. (NVO)

(3 January 2017)

NVO Business Summary

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

NVO Fundamentals

  • Price to Earnings: 16.31
  • Earnings Per Share: $2.19
  • Market Cap: 70.3B
  • Current Ratio: 1.24
  • Return on Equity: 88.71%

Dividend Yield: 1.20%

  • Cash to Debt Ratio: 36.36

Balance Sheet ($ in DKK Millions)

  • Total Assets decreased $4,459.
  • Total Liabilities increased $5,140.
  • Total Stockholder Equity decreased $5,642.

Income Statement ($ in DKK Millions)

  • Total Sales increased $3,157. 4%.
  • Operating Profit decreased $1,093, or (3%).
  • Net Profit increased $2,624, or 10%.
  • Diluted Earnings Per Share increased from $11.50 from $10.28, or 12%.

Cash Flow Statement ($ in DKK Millions)

  • Net Cash provided by operating activities increased $8,993.
  • Net Cash used in investing activities increased $2,656.
  • Net Cash used in financing activities increased $9,138.
  • Cash and Cash Equivalents at end of period decreased $773.

Added Notes

  • Novo Nordisk Reports Received FDA Approval of – Tresiba for Use in Children, Adolescents with Diabetes


  • Given it’s dividend yield, and it’s attractive P/E of 15.5, I am midly bullish on NVO. I think it could see some short term downside given the charts, however, I remain bullish on this stock at around $30.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s